A novel indication of platonin, a therapeutic immunomodulating medicine, on neuroprotection against ischemic stroke in mice

Sci Rep. 2017 Feb 6:7:42277. doi: 10.1038/srep42277.

Abstract

Thrombosis and stroke are major causes of disability and death worldwide. However, the regular antithrombotic drugs may have unsatisfactory results and side effects. Platonin, a cyanine photosensitizing dye, has been used to treat trauma, ulcers and some acute inflammation. Here, we explored the neuroprotective effects of platonin against middle cerebral artery occlusion (MCAO)-induced ischemic stroke in mice. Platonin(200 μg/kg) substantially reduced cerebral infarct volume, brain edema, neuronal cell death and neurological deficit scores, and improved the MCAO-reduced locomotor activity and rotarod performance. Platonin(5-10 μM) potently inhibited platelet aggregation and c-Jun NH2-terminal kinase (JNK) phosphorylation in collagen-activated platelets. The antiaggregation effect did not affect bleeding time but increased occlusion time in platonin(100 and 200 μg/kg)-treated mice. Platonin(2-10 μM) was potent in diminishing collagen- and Fenton reaction-induced OH formation. Platonin(5-10 μM) also suppressed the expression of nitric oxide, inducible nitric oxide synthase, cyclooxygenase-2, interleukin-1β, and JNK phosphorylation in lipopolysaccharide-stimulated macrophages. MCAO-induced expression of 3-nitrotyrosine and Iba1 was apparently attenuated in platonin(200 μg/kg)-treated mice. In conclusion, platonin exhibited remarkable neuroprotective properties against MCAO-induced ischemia in a mouse model through its antiaggregation, antiinflammatory and antiradical properties. The observed therapeutic efficacy of platonin may consider being a novel medcine against ischemic stroke.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Behavior, Animal
  • Brain Ischemia / complications
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / pathology
  • Cell Death / drug effects
  • Collagen
  • Disease Models, Animal
  • Free Radicals / metabolism
  • Humans
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use*
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / drug therapy
  • Infarction, Middle Cerebral Artery / pathology
  • Inflammation Mediators / metabolism
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • Lipopolysaccharides
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Macrophages / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Models, Biological
  • Neurons / drug effects
  • Neurons / metabolism
  • Neurons / pathology
  • Neuroprotection* / drug effects
  • Neuroprotective Agents / chemistry
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Phosphorylation
  • Platelet Aggregation / drug effects
  • RAW 264.7 Cells
  • Stroke / complications
  • Stroke / drug therapy*
  • Thiazoles / chemistry
  • Thiazoles / pharmacology
  • Thiazoles / therapeutic use*
  • Time Factors

Substances

  • Anti-Inflammatory Agents
  • Free Radicals
  • Immunologic Factors
  • Inflammation Mediators
  • Lipopolysaccharides
  • Neuroprotective Agents
  • Thiazoles
  • platonin
  • Collagen
  • JNK Mitogen-Activated Protein Kinases